Press release
Idiopathic Pulmonary Fibrosis Pipeline, Clinical Trials, NDA Approvals, and Emerging Drugs (2023) | Companies- Roche, Novartis, Vicore Pharma, and Others
Idiopathic Pulmonary Fibrosis Pipeline
In the Idiopathic Pulmonary Fibrosis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Idiopathic Pulmonary Fibrosis NDA approvals (if any), and product development activities comprising the technology, Idiopathic Pulmonary Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Idiopathic Pulmonary Fibrosis Pipeline treatment landscape of the report, click here @ Idiopathic Pulmonary Fibrosis Pipeline Outlook- https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Insight Report
• DelveInsight's analysis presents Idiopathic Pulmonary Fibrosis Pipeline with 80+ active players in the domain investigating 80+ pipeline therapies.
• The leading Idiopathic Pulmonary Fibrosis Companies include Mission Therapeutics, Lung Therapeutics, Theravance Biopharma, Pliant Therapeutics, Vicore Pharma, Galecto Biotech, FibroGen, Roche, Kinarus, Insmed, Avalyn Pharmaceuticals, Bridge Biotherapeutics, and others.
• Promising Idiopathic Pulmonary Fibrosis pipeline therapies include DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, KIN001-IPF, Treprostinil palmitil, AP01, BBT-877, and others.
• On February 2022, Endeavor BioMedicines, announced the completion of a $101 million Series B financing, led by Ally Bridge Group and Avidity Partners. New investors participating in the round include Perceptive Advisors, Piper Heartland Healthcare Capital, Revelation Partners, funds managed by Tekla Capital Management LLC, and funds and accounts advised by T. Rowe Price Associates, Inc. Existing investors Omega Funds and Longitude Capital also participated. Proceeds will support the advancement of Endeavor's pipeline programs, including ENV-101 (taladegib), a small molecule inhibitor of the PTCH1 receptor in the Hedgehog signaling pathway for the treatment of cancer and idiopathic pulmonary fibrosis (IPF), as well as ENV-201, a potentially best-in-class small molecule inhibitor of ULK1/2 for the treatment of KRAS-driven cancers.
Idiopathic Pulmonary Fibrosis Overview
Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that is found to affect the middle-aged and older adults; and affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis) which increases irreversibly over time.
For further information, refer to the detailed Idiopathic Pulmonary Fibrosis Unmet Needs, Idiopathic Pulmonary Fibrosis Market Drivers, and Idiopathic Pulmonary Fibrosis Market Barriers, click here for Idiopathic Pulmonary Fibrosis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Idiopathic Pulmonary Fibrosis Emerging Drugs Profile
• PRM-151: Hoffmann-La Roche
• Pamrevlumab: FibroGen
• Tipelukast: MediciNova
• PLN-74809: Pliant Therapeutics
• GLPG4716: Galapagos NV
Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment
There are approx. 80+ Idiopathic Pulmonary Fibrosis companies which are developing the therapies for Idiopathic Pulmonary Fibrosis. The Idiopathic Pulmonary Fibrosis companies which have their Idiopathic Pulmonary Fibrosis drug candidates in the most advanced stage, i.e. phase III include, Hoffmann-La Roche.
Request a sample and discover the recent advances in Idiopathic Pulmonary Fibrosis Ongoing Clinical Trial Analysis and Medications, click here @ Idiopathic Pulmonary Fibrosis Treatment Landscape- https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Idiopathic Pulmonary Fibrosis Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Idiopathic Pulmonary Fibrosis Therapeutics Market include-
Mission Therapeutics, Lung Therapeutics, Theravance Biopharma, Pliant Therapeutics, Vicore Pharma, Galecto Biotech, FibroGen, Roche, Kinarus, Insmed, Avalyn Pharmaceuticals, Bridge Biotherapeutics, and others.
Dive deep into rich insights for drugs for Idiopathic Pulmonary Fibrosis Pipeline, click here @ Idiopathic Pulmonary Fibrosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report
• Coverage- Global
• Idiopathic Pulmonary Fibrosis Companies- Mission Therapeutics, Lung Therapeutics, Theravance Biopharma, Pliant Therapeutics, Vicore Pharma, Galecto Biotech, FibroGen, Roche, Kinarus, Insmed, Avalyn Pharmaceuticals, Bridge Biotherapeutics, and others
• Idiopathic Pulmonary Fibrosis Pipeline Therapies- DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, KIN001-IPF, Treprostinil palmitic, AP01, BBT-877, and others
• Idiopathic Pulmonary Fibrosis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Idiopathic Pulmonary Fibrosis Merger and acquisitions, Idiopathic Pulmonary Fibrosis Licensing Activities @ Idiopathic Pulmonary Fibrosis Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Idiopathic Pulmonary Fibrosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Idiopathic Pulmonary Fibrosis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. PRM-151: Hoffmann-La Roche
9. Mid Stage Products (Phase II)
10. Tipelukast: MediciNova
11. Early Stage Products (Phase I/II)
12. Lung stem cells: Regend Therapeutics
13. Early Stage Products (Phase I)
14. LTI-03: Lung Therapeutics
15. Preclinical and Discovery Stage Products
16. AD-214: Adalta
17. Inactive Products
18. Idiopathic Pulmonary Fibrosis Key Companies
19. Idiopathic Pulmonary Fibrosis Key Products
20. Idiopathic Pulmonary Fibrosis- Unmet Needs
21. Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers
22. Idiopathic Pulmonary Fibrosis- Future Perspectives and Conclusion
23. Idiopathic Pulmonary Fibrosis Analyst Views
24. Idiopathic Pulmonary Fibrosis Key Companies
25. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/conference-coverage-car-tcr-summit
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Idiopathic Pulmonary Fibrosis Pipeline, Clinical Trials, NDA Approvals, and Emerging Drugs (2023) | Companies- Roche, Novartis, Vicore Pharma, and Others here
News-ID: 3094882 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Idiopathic
Idiopathic Pulmonary Fibrosis Market Size & Share Analysis
The new report published by The Business Research Company, titled Idiopathic Pulmonary Fibrosis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $3.89…
Idiopathic Pulmonary Fibrosis Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Idiopathic Pulmonary Fibrosis Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Pulmonary Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Idiopathic Pulmonary Fibrosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Chronic Idiopathic Myelofibrosis Market 2022 | Detailed Report
The Chronic Idiopathic Myelofibrosis report understands the current and future competitive scenario across types, countries, and applications.It provides accurate, up-to-date analysis of markets and companies.The report use reliable information and analysis to gain a deeper understanding of the current factors impacting the industry.
The Chronic Idiopathic Myelofibrosis report provides exact and accurate data that helps companies of all sizes to make timely decisions. Furthermore, the report provides robust solutions to customers,…
Idiopathic Membranous Nephropathy Treatment Market to Witness Significant Growth …
Idiopathic membranous nephropathy a glomerular disease usually of abrupt onset and associated with the nephrotic syndrome. Membranous nephropathy occurs when the small blood vessels in the kidney (glomeruli), which filter wastes from the blood, become damaged and thickened. As a result, proteins leak from the damaged blood vessels into the urine (proteinuria).
R&D in idiopathic membranous nephropathy is expected to aid in growth of the idiopathic membranous nephropathy treatment market. In…
Global Idiopathic Scoliosis Treatment Market Size by Type (Infantile Idiopathic, …
Global Idiopathic Scoliosis Treatment Market Research report provides vital information related to the overall market and forecast from 2019 to 2026. This report includes the in-depth analysis of market size, share, growth, trends and regional demand and top layers the Idiopathic Scoliosis Treatment Market. The major players dominating the market are focused upon throughout the by analyzing their revenue, their business summary, product segmentation along with the latest developments.
Get Sample…
Chronic Idiopathic Constipation Market Research Report 2024
Constipation can be defined as reduced stool frequency or difficulty in passing stool. The frequency may be reduced to less than three times a week. Reduced or difficult stool passage includes hard lumpy stools, incomplete bowel movements, straining, incomplete evacuation, and need for manual removal of stool. Chronic idiopathic constipation (CIC) can be defined as more chronic or severe continuation of these above symptoms. Many times the cause of constipation…
